-
Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in the UK
Sep 9, 2025, 16:22 PM -
Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework
Sep 9, 2025, 16:22 PM -
What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Sep 9, 2025, 16:22 PM -
Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines
Sep 9, 2025, 16:22 PM -
Satisfact-Home: Perception of Care Quality and Quality of Life in Patients With Solid Tumors Receiving Immune Checkpoint Inhibitors (ICIs) Therapy From Hospital To Home: A French Multicenter Prospective Observational Study
Sep 9, 2025, 16:22 PM -
High-Fidelity Synthetic Patient Pathway Generation and Validation for NSCLC Using A Tabular Variational Autoencoder (TVAE)
Sep 9, 2025, 16:22 PM -
A Systematic Review of Trends From Migraine Preference Studies
Sep 9, 2025, 16:22 PM -
Assessing the Cost-Effectiveness of Subcutaneous Semaglutide 2.4 mg in the Management of Individuals With Obesity and Prediabetes in England
Sep 9, 2025, 16:22 PM -
Evaluation of the Use of ChatGPT in Data Extraction for Systematic Literature Reviews: Friend, Foe, or Fiction?
Sep 9, 2025, 16:22 PM -
Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data
Sep 9, 2025, 16:22 PM -
Societal and Economic Impact of Long-Acting Injectable Buprenorphine (LAIB) Compared With Standard Opioid Substitution Therapy (OST) in France
Sep 9, 2025, 16:22 PM -
Evaluation of the Measurement Properties of the German LupusPRO™ for Swiss-German SLE Patients
Sep 9, 2025, 16:22 PM -
Evaluation of the Societal Impact of Emicizumab in France Since Its Market Authorization: Budget Impact From 2018 to 2024
Sep 9, 2025, 16:22 PM -
Forecasting Uptake of Novel Drugs Used for Atopic Dermatitis in Sweden Based on Historic RWE
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Obecabtagene Autoleucel for Adults With Relapsed/Refractory B-cell ALL From a US Payer Perspective
Sep 9, 2025, 16:22 PM -
Life Years Generated for Relapsed/Refractory Mantle Cell Lymphoma Patients Managed on CAR-T in an England NHS Setting
Sep 9, 2025, 16:22 PM -
Real-World Healthcare Resource Utilization and Related Costs Associated With Schizophrenia in the Brazilian Private Market
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of AI-Assisted Ultrasound for Breast Cancer Detection in Taiwan
Sep 9, 2025, 16:22 PM -
Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study
Sep 9, 2025, 16:22 PM
